Citius Oncology (NASDAQ:CTOR) Shares Down 2.5% – Should You Sell?

Citius Oncology, Inc. (NASDAQ:CTOR) traded down 2.5% during trading on Friday . The stock traded as low as $1.15 and last traded at $1.17. 45,075 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 101,126 shares. The stock had previously closed at $1.20.

Analyst Upgrades and Downgrades

Separately, Maxim Group assumed coverage on shares of Citius Oncology in a report on Wednesday, November 27th. They issued a “buy” rating and a $3.00 price target on the stock.

Citius Oncology Stock Down 2.5 %

The company has a 50 day simple moving average of $1.18. The company has a current ratio of 0.34, a quick ratio of 0.08 and a debt-to-equity ratio of 0.08.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings results on Friday, February 14th. The company reported ($0.09) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Citius Oncology

A hedge fund recently raised its stake in Citius Oncology stock. IFP Advisors Inc raised its holdings in Citius Oncology, Inc. (NASDAQ:CTOR) by 173.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,215 shares of the company’s stock after acquiring an additional 14,080 shares during the quarter. IFP Advisors Inc’s holdings in Citius Oncology were worth $26,000 as of its most recent filing with the Securities and Exchange Commission. 70.52% of the stock is owned by institutional investors and hedge funds.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.